BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450-6. [PMID: 33762733 DOI: 10.1038/s41586-021-03362-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 41.0] [Reference Citation Analysis]
Number Citing Articles
1 Xia Y, Gao B, Zhang X. Targeting mitochondrial quality control of T cells: Regulating the immune response in HCC. Front Oncol 2022;12:993437. [DOI: 10.3389/fonc.2022.993437] [Reference Citation Analysis]
2 Leyh C, Heucke N, Schotten C, Büchter M, Bechmann LP, Wichert M, Dechêne A, Herrmann K, Heider D, Sydor S, Lemmer P, Ludwig JM, Pospiech J, Theysohn J, Damm R, March C, Powerski M, Pech M, Özcürümez M, Weigt J, Keitel V, Lange CM, Schmidt H, Canbay A, Best J, Gerken G, Manka PP. LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers 2022;14:4584. [DOI: 10.3390/cancers14194584] [Reference Citation Analysis]
3 Costante F, Airola C, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. World J Gastrointest Oncol 2022; 14(9): 1622-1636 [DOI: 10.4251/wjgo.v14.i9.1622] [Reference Citation Analysis]
4 Liu H, Qin X, Xu Z, Wu M, Lu T, Zhou S, Yao N, Liu S, Shao Y, Han Z. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China. Front Genet 2022;13:1000448. [DOI: 10.3389/fgene.2022.1000448] [Reference Citation Analysis]
5 Yu S, Wang J, Zheng H, Wang R, Johnson N, Li T, Li P, Lin J, Li Y, Yan J, Zhang Y, Zhu Z, Ding X. Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. J Hepatocell Carcinoma 2022;9:855-67. [PMID: 36051860 DOI: 10.2147/JHC.S377768] [Reference Citation Analysis]
6 Sasaki-tanaka R, Ray R, Moriyama M, Ray RB, Kanda T. Molecular Changes in Relation to Alcohol Consumption and Hepatocellular Carcinoma. IJMS 2022;23:9679. [DOI: 10.3390/ijms23179679] [Reference Citation Analysis]
7 Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma 2022;9:823-37. [PMID: 35996397 DOI: 10.2147/JHC.S368208] [Reference Citation Analysis]
8 Carloni R, Rizzo A, Cusmai A, Palloni A, Federico AD, Marco MD, Massafra R, Fanizzi A, Palmiotti G, Brandi G. Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Med Chem 2022. [PMID: 35997677 DOI: 10.4155/fmc-2022-0045] [Reference Citation Analysis]
9 Nishio T, Ito T, Hata K, Taura K, Hatano E. Current status of liver transplantation for non‐B non‐C liver cirrhosis and hepatocellular carcinoma. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12612] [Reference Citation Analysis]
10 Salem R, Greten TF. Interventional radiology meets immuno-oncology for hepatocellular carcinoma. J Hepatol 2022:S0168-8278(22)03003-3. [PMID: 35988688 DOI: 10.1016/j.jhep.2022.08.003] [Reference Citation Analysis]
11 Tomonari T, Tani J, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Morishita A, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Masaki T, Takayama T. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. Cancer Med 2022. [PMID: 35964253 DOI: 10.1002/cam4.5145] [Reference Citation Analysis]
12 Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
13 Fulgenzi CAM, D'Alessio A, Airoldi C, Scotti L, Demirtas CO, Gennari A, Cortellini A, Pinato DJ. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials. Eur J Cancer 2022;174:57-67. [PMID: 35970037 DOI: 10.1016/j.ejca.2022.06.058] [Reference Citation Analysis]
14 Abuduwaili W, Wang X, Huang AT, Sun JL, Xu RC, Zhang GC, Liu ZY, Wang F, Zhu CF, Liu TT, Dong L, Zhu JM, Weng SQ, Li Y, Shen XZ. Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2022. [PMID: 35951459 DOI: 10.1021/acsami.2c07247] [Reference Citation Analysis]
15 Zhang P, Chen Z, Kuang H, Liu T, Zhu J, Zhou L, Wang Q, Xiong X, Meng Z, Qiu X, Jacks R, Liu L, Li S, Lumeng CN, Li Q, Zhou X, Lin JD. Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment. Cell Metab 2022:S1550-4131(22)00309-6. [PMID: 35973424 DOI: 10.1016/j.cmet.2022.07.010] [Reference Citation Analysis]
16 Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li Y, Gao C, Lu H, Wang X, Cao P, Chen H, Lu S, Zhou G. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat Commun 2022;13:4594. [PMID: 35933472 DOI: 10.1038/s41467-022-32283-3] [Reference Citation Analysis]
17 Ma X, Chan TA. Solving the puzzle of what makes immunotherapies work. Trends Cancer 2022:S2405-8033(22)00151-0. [PMID: 35933298 DOI: 10.1016/j.trecan.2022.06.011] [Reference Citation Analysis]
18 Kim N, Cheng JC, Ohri N, Huang W, Kimura T, Zeng ZC, Lee VHF, Kay CS, Seong J. Does HCC Etiology Impact the Efficacy of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma? An Asian Liver Radiation Therapy Group Study. JHC 2022;Volume 9:707-15. [DOI: 10.2147/jhc.s377810] [Reference Citation Analysis]
19 Petrelli F, Manara M, Colombo S, De Santi G, Ghidini M, Mariani M, Iaculli A, Rausa E, Rampulla V, Arru M, Viti M, Lonati V, Ghidini A, Luciani A, Facciorusso A. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Neoplasia 2022;30:100809. [DOI: 10.1016/j.neo.2022.100809] [Reference Citation Analysis]
20 An M, Wang W, Zhang J, Till BG, Zhao L, Huang H, Yang Y, Li T, Han L, Zhang X, Qin P, Wang Y, Zhang M, Cui H, Gao Q, Wang Z. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy. Cancer Immunol Immunother 2022. [PMID: 35907016 DOI: 10.1007/s00262-022-03254-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Marsh-Wakefield F, Ferguson AL, Liu K, Santhakumar C, McCaughan G, Palendira U. Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:17588359221113270. [PMID: 35898965 DOI: 10.1177/17588359221113270] [Reference Citation Analysis]
22 Kim JE, Kim E, Lee JW. TM4SF5-Mediated Regulation of Hepatocyte Transporters during Metabolic Liver Diseases. IJMS 2022;23:8387. [DOI: 10.3390/ijms23158387] [Reference Citation Analysis]
23 Adolph TE, Meyer M, Schwärzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35906289 DOI: 10.1038/s41575-022-00658-y] [Reference Citation Analysis]
24 Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? . World J Gastroenterol 2022; 28(28): 3595-3607 [DOI: 10.3748/wjg.v28.i28.3595] [Reference Citation Analysis]
25 Stefanini B, Bucci L, Santi V, Reggidori N, Rampoldi D, Lani L, Granito A, Sangiovanni A, Cabibbo G, Farinati F, Campani C, Foschi FG, Svegliati-Baroni G, Raimondo G, Gasbarrini A, Mega A, Biasini E, Sacco R, Morisco F, Caturelli E, Vidili G, Azzaroli F, Giannini EG, Rapaccini GL, Brunetto MR, Masotto A, Nardone G, Marco MD, Magalotti D, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Potential feasibility of Atezolizumab-Bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. Dig Liver Dis 2022:S1590-8658(22)00587-4. [PMID: 35906166 DOI: 10.1016/j.dld.2022.07.003] [Reference Citation Analysis]
26 Malone CD, Egbulefu C, Zheleznyak A, Polina J, Karmakar P, Black K, Shokeen M, Achilefu S. Activation of nano-photosensitizers by Y-90 microspheres to enhance oxidative stress and cell death in hepatocellular carcinoma. Sci Rep 2022;12:12748. [PMID: 35882949 DOI: 10.1038/s41598-022-17185-0] [Reference Citation Analysis]
27 Ilieva M, Dao J, Miller HE, Madsen JH, Bishop AJR, Kauppinen S, Uchida S. Systematic Analysis of Long Non-Coding RNA Genes in Nonalcoholic Fatty Liver Disease. ncRNA 2022;8:56. [DOI: 10.3390/ncrna8040056] [Reference Citation Analysis]
28 Xiong J, Wang QQ. Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00182-5. [PMID: 35907687 DOI: 10.1016/j.hbpd.2022.07.006] [Reference Citation Analysis]
29 Da Fonseca LG, Hashizume PH, de Oliveira IS, Izquierdo-sanchez L, Saud LRDC, Xerfan MP, Alves VAF, de Mello ES, Herman P, Banales JM, Oliveira CP, Carrilho FJ. Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence. Cancers 2022;14:3483. [DOI: 10.3390/cancers14143483] [Reference Citation Analysis]
30 Marron TU, Schwartz M, Corbett V, Merad M. Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:571-81. [PMID: 35794901 DOI: 10.2147/JHC.S340935] [Reference Citation Analysis]
31 Xu L, Zou C, Zhang S, Chu TSM, Zhang Y, Chen W, Zhao C, Yang L, Xu Z, Dong S, Yu H, Li B, Guan X, Hou Y, Kong FM. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol 2022;15:87. [PMID: 35799264 DOI: 10.1186/s13045-022-01307-2] [Reference Citation Analysis]
32 Lin J, Dai Y, Sang C, Song G, Xiang B, Zhang M, Dong L, Xia X, Ma J, Shen X, Ji S, Zhang S, Wang M, Fang H, Zhang X, Wang X, Zhang B, Zhou J, Fan J, Zhou H, Gao D, Gao Q. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities. J Immunother Cancer 2022;10:e004892. [PMID: 35863823 DOI: 10.1136/jitc-2022-004892] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Kelley RK, Rimassa L, Cheng A, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo B, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00326-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
34 Ji F, Nguyen MH. Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00383-7] [Reference Citation Analysis]
35 Lee C, Chan SL, Chon HJ. Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma? Cancers 2022;14:3213. [DOI: 10.3390/cancers14133213] [Reference Citation Analysis]
36 Zhang Y, Zhang X, Kuang M, Yu J. Emerging insights on immunotherapy in liver cancer. Antioxid Redox Signal 2022. [PMID: 35754339 DOI: 10.1089/ars.2022.0047] [Reference Citation Analysis]
37 Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatol Int 2022. [PMID: 35749019 DOI: 10.1007/s12072-022-10358-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 2022. [PMID: 35739268 DOI: 10.1038/s41591-022-01868-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci Transl Med 2022;14:eabo4474. [PMID: 35731891 DOI: 10.1126/scitranslmed.abo4474] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Shigefuku R, Yoshikawa K, Tsukimoto M, Owa H, Tamai Y, Tameda M, Ogura S, Sugimoto R, Tanaka H, Eguchi A, Sugimoto K, Hasegawa H, Iwasa M, Nakagawa H. A Case of Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab. Intern Med 2022. [PMID: 35732454 DOI: 10.2169/internalmedicine.9701-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol 2022:S0168-8278(22)00375-0. [PMID: 35750137 DOI: 10.1016/j.jhep.2022.06.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Current therapies and new developments in NASH. Gut 2022:gutjnl-2021-326874. [PMID: 35710299 DOI: 10.1136/gutjnl-2021-326874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Pourhamzeh M, Asadian S, Mirzaei H, Minaei A, Shahriari E, Shpichka A, Es HA, Timashev P, Hassan M, Vosough M. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Mol Cell Biochem 2022. [PMID: 35708866 DOI: 10.1007/s11010-022-04483-4] [Reference Citation Analysis]
44 Lujambio A, Sarobe P. Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy. J Hepatol 2022:S0168-8278(22)00362-2. [PMID: 35714813 DOI: 10.1016/j.jhep.2022.05.038] [Reference Citation Analysis]
45 Chapin WJ, Hwang WT, Karasic TB, McCarthy AM, Kaplan DE. Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Med 2022. [PMID: 35652419 DOI: 10.1002/cam4.4906] [Reference Citation Analysis]
46 Ahmad MI, Khan MU, Kodali S, Shetty A, Bell SM, Victor D. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. JHC 2022;Volume 9:477-96. [DOI: 10.2147/jhc.s344559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology 2022;75:1604-26. [PMID: 35253934 DOI: 10.1002/hep.32447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
48 Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2022;10:e004779. [PMID: 35738801 DOI: 10.1136/jitc-2022-004779] [Reference Citation Analysis]
49 Bejjani AC, Finn RS. Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations. J Clin Oncol 2022;:JCO2102605. [PMID: 35649192 DOI: 10.1200/JCO.21.02605] [Reference Citation Analysis]
50 Sheng J, Zhang J, Wang L, Tano V, Tang J, Wang X, Wu J, Song J, Zhao Y, Rong J, Cheng F, Wang J, Shen Y, Wen L, He J, Zhang H, Li T, Zhang Q, Bai X, Lu Z, Liang T. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. Gut 2022;71:1176-91. [PMID: 34253573 DOI: 10.1136/gutjnl-2021-324339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
51 Li A, Wu B, Yin L, Yang X, Cheng K, Guo J, Wu M. Right hepatic vein reconstruction in middle hepatectomy: A case report. International Journal of Surgery Case Reports 2022;95:107188. [DOI: 10.1016/j.ijscr.2022.107188] [Reference Citation Analysis]
52 Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. Int J Clin Oncol 2022. [PMID: 35633441 DOI: 10.1007/s10147-022-02174-0] [Reference Citation Analysis]
53 Liu Y, Xu L, Hao C, Wu J, Jia X, Ding X, Lin C, Zhu H, Zhang Y. Identification and Validation of Novel Immune-Related Alternative Splicing Signatures as a Prognostic Model for Colon Cancer. Front Oncol 2022;12:866289. [DOI: 10.3389/fonc.2022.866289] [Reference Citation Analysis]
54 Alvarez M, Benhammou JN, Darci-Maher N, French SW, Han SB, Sinsheimer JS, Agopian VG, Pisegna JR, Pajukanta P. Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival. Genome Med 2022;14:50. [PMID: 35581624 DOI: 10.1186/s13073-022-01055-5] [Reference Citation Analysis]
55 Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacol Res 2022;181:106261. [PMID: 35588918 DOI: 10.1016/j.phrs.2022.106261] [Reference Citation Analysis]
56 Rizzo A, Ricci AD. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Expert Review of Precision Medicine and Drug Development 2022;7:50-7. [DOI: 10.1080/23808993.2022.2075724] [Reference Citation Analysis]
57 Fiorucci S, Rapacciuolo P, Fiorillo B, Roselli R, Marchianò S, Di Giorgio C, Bordoni M, Bellini R, Cassiano C, Conflitti P, Catalanotti B, Limongelli V, Sepe V, Biagioli M, Zampella A. Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease. Front Pharmacol 2022;13:858137. [PMID: 35559268 DOI: 10.3389/fphar.2022.858137] [Reference Citation Analysis]
58 Goh MJ, Kang W, Jeong WK, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. Sci Rep 2022;12:7647. [PMID: 35538112 DOI: 10.1038/s41598-022-11736-1] [Reference Citation Analysis]
59 Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;:1-11. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Reference Citation Analysis]
60 Bárcena-Varela M. Revealing anti-PD-1 resistance mechanisms in HCC: a path towards novel combination immunotherapies. J Hepatol 2022:S0168-8278(22)00255-0. [PMID: 35513202 DOI: 10.1016/j.jhep.2022.04.020] [Reference Citation Analysis]
61 Sung PS, Park DJ, Roh PR, Mun KD, Cho SW, Lee GW, Jung ES, Lee SH, Jang JW, Bae SH, Choi JY, Choi J, Ahn J, Yoon SK. Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy. J Immunother Cancer 2022;10:e003618. [PMID: 35577505 DOI: 10.1136/jitc-2021-003618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Song BS, Moon JS, Tian J, Lee HY, Sim BC, Kim SH, Kang SG, Kim JT, Nga HT, Benfeitas R, Kim Y, Park S, Wolfe RR, Eun HS, Shong M, Lee S, Kim IY, Yi HS. Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion. J Immunother Cancer 2022;10:e004337. [PMID: 35580931 DOI: 10.1136/jitc-2021-004337] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
63 Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun 2022. [PMID: 35481940 DOI: 10.1002/hep4.1927] [Reference Citation Analysis]
64 Pallett LJ, Maini MK. Liver-resident memory T cells: life in lockdown. Semin Immunopathol 2022. [PMID: 35482059 DOI: 10.1007/s00281-022-00932-w] [Reference Citation Analysis]
65 Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Clark W, Gilroy K, Hedley A, Nixon C, Luli S, Laszczewska M, Pinyol R, Esteban-Fabró R, Willoughby CE, Haber PK, Andreu-Oller C, Rahbari M, Fan C, Pfister D, Raman S, Wilson N, Müller M, Collins A, Geh D, Fuller A, McDonald D, Hulme G, Filby A, Cortes-Lavaud X, Mohamed NE, Ford CA, Raffo Iraolagoitia XL, McFarlane AJ, McCain MV, Ridgway RA, Roberts EW, Barry ST, Graham GJ, Heikenwälder M, Reeves HL, Llovet JM, Carlin LM, Bird TG, Sansom OJ, Mann DA. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 2022:gutjnl-2021-326259. [PMID: 35477863 DOI: 10.1136/gutjnl-2021-326259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Dudek M, Tacke F. Immature neutrophils bring anti-PD-1 therapy in NASH-HCC to maturity. Gut 2022:gutjnl-2022-327396. [PMID: 35477865 DOI: 10.1136/gutjnl-2022-327396] [Reference Citation Analysis]
67 Macek Jilkova Z. Gamma delta T cells in hepatocellular carcinoma: Sunrise of new therapy based on Vδ2 T cells? Clin Transl Med 2022;12:e834. [PMID: 35451575 DOI: 10.1002/ctm2.834] [Reference Citation Analysis]
68 Hamaguchi K, Miyanishi K, Osuga T, Tanaka S, Ito R, Sakamoto H, Kubo T, Ohnuma H, Murase K, Takada K, Nagayama M, Kimura Y, Mizuguchi T, Takemasa I, Kato J. Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/β-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma. Cancers 2022;14:2066. [DOI: 10.3390/cancers14092066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Machairas N, Tsilimigras DI, Pawlik TM. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers 2022;14:2018. [DOI: 10.3390/cancers14082018] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Akce M, El-rayes BF, Bekaii-saab TS. Frontline therapy for advanced hepatocellular carcinoma: an update. Therap Adv Gastroenterol 2022;15:175628482210861. [DOI: 10.1177/17562848221086126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Wabitsch S, Mccallen JD, Kamenyeva O, Ruf B, Mcvey JC, Kabat J, Walz JS, Rotman Y, Bauer KC, Craig AJ, Pouzolles M, Phadke I, Catania V, Green BL, Fu C, Diggs LP, Heinrich B, Wang XW, Ma C, Greten TF. Metformin treatment rescues CD8+ T cell response to immune checkpoint inhibitor therapy in mice with NAFLD. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Barsch M, Salié H, Schlaak AE, Zhang Z, Hess M, Mayer LS, Tauber C, Otto-mora P, Ohtani T, Nilsson T, Wischer L, Winkler F, Manne S, Rech A, Schmitt-graeff A, Bronsert P, Hofmann M, Neumann-haefelin C, Boettler T, Fichtner-feigl S, van Boemmel F, Berg T, Rimassa L, Di Tommaso L, Saeed A, D’alessio A, Pinato DJ, Bettinger D, Binder H, Wherry EJ, Schultheiss M, Thimme R, Bengsch B. T cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
73 Boettler T, Csernalabics B, Salié H, Luxenburger H, Wischer L, Alizei ES, Zoldan K, Krimmel L, Bronsert P, Schwabenland M, Prinz M, Mogler C, Neumann-haefelin C, Thimme R, Hofmann M, Bengsch B. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
74 Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 2022;3:386-401. [PMID: 35484418 DOI: 10.1038/s43018-022-00357-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
75 Ramadori P, Kam S, Heikenwalder M. T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis. Hepatology 2022;75:1038-49. [PMID: 35023202 DOI: 10.1002/hep.32336] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Rizzo A, Cusmai A, Gadaleta-Caldarola G, Palmiotti G. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Expert Rev Gastroenterol Hepatol 2022;16:333-9. [PMID: 35403533 DOI: 10.1080/17474124.2022.2064273] [Reference Citation Analysis]
77 Li D, Yao Y, Rao Y, Huang X, Wei L, You Z, Zheng G, Hou X, Su Y, Varghese Z, Moorhead JF, Chen Y, Ruan XZ. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma. J Exp Clin Cancer Res 2022;41:116. [PMID: 35354475 DOI: 10.1186/s13046-022-02306-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Kim BK, Cheon J, Kim H, Kang B, Ha Y, Kim DY, Hwang SG, Chon YE, Chon HJ. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers (Basel) 2022;14:1747. [PMID: 35406518 DOI: 10.3390/cancers14071747] [Reference Citation Analysis]
79 Himmelsbach V, Pinter M, Scheiner B, Venerito M, Sinner F, Zimpel C, Marquardt JU, Trojan J, Waidmann O, Finkelmeier F. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. Cancers (Basel) 2022;14:1722. [PMID: 35406493 DOI: 10.3390/cancers14071722] [Reference Citation Analysis]
80 Taylor A, Siddiqui MK, Ambery P, Armisen J, Challis BG, Haefliger C, Pearson ER, Doney ASF, Dillon JF, Palmer CNA. Metabolic dysfunction-related liver disease as a risk factor for cancer. BMJ Open Gastroenterol 2022;9:e000817. [PMID: 35338048 DOI: 10.1136/bmjgast-2021-000817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
81 Akuta N, Kawamura Y, Suzuki F, Kobayashi M, Arase Y, Saitoh S, Muraishi N, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Ikeda K, Kumada H. Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. Hepatol Int. [DOI: 10.1007/s12072-022-10313-y] [Reference Citation Analysis]
82 Chan LL, Chan SL. Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Cancers (Basel) 2022;14:1526. [PMID: 35326677 DOI: 10.3390/cancers14061526] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Komuta M, Ueno A, Sakamoto M. The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer. Hepatology 2022. [PMID: 35263454 DOI: 10.1002/hep.32452] [Reference Citation Analysis]
84 Ponziani FR, De Luca A, Picca A, Marzetti E, Petito V, Del Chierico F, Reddel S, Paroni Sterbini F, Sanguinetti M, Putignani L, Gasbarrini A, Pompili M. Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma. Hepatol Commun 2022. [PMID: 35261212 DOI: 10.1002/hep4.1905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022. [PMID: 35239194 DOI: 10.1002/hep.32439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Muhammed A, D'Alessio A, Enica A, Talbot T, Fulgenzi CAM, Nteliopoulos G, Goldin RD, Cortellini A, Pinato DJ. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35236211 DOI: 10.1080/14737159.2022.2049244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
87 Wong AM, Ding X, Wong AM, Xu M, Zhang L, Leung HH, Chan AW, Song QX, Kwong J, Chan LK, Man M, He M, Chen J, Zhang Z, You W, Lau C, Yu A, Wei Y, Yuan Y, Lai PB, Zhao J, Man K, Yu J, Kahn M, Wong N. Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
89 Mirshahi F, Aqbi HF, Isbell M, Manjili SH, Guo C, Saneshaw M, Dozmorov M, Khosla A, Wack K, Carrasco-Zevallos OM, Idowu MO, Wang XY, Sanyal AJ, Manjili MH, Bandyopadhyay D. Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. Cell Rep 2022;38:110454. [PMID: 35235789 DOI: 10.1016/j.celrep.2022.110454] [Reference Citation Analysis]
90 Lombardi R, Piciotti R, Dongiovanni P, Meroni M, Fargion S, Fracanzani AL. PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. Int J Mol Sci 2022;23:2707. [PMID: 35269846 DOI: 10.3390/ijms23052707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Zaki MYW, Fathi AM, Samir S, Eldafashi N, William KY, Nazmy MH, Fathy M, Gill US, Shetty S. Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:1255. [PMID: 35267563 DOI: 10.3390/cancers14051255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, Roessler D, Khaled NB, Jeschke M, Ludwig JM, Marquardt JU, Weinmann A, Pinter M, Lange CM, Vogel A, Saborowski A. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol 2022;14:175883592210802. [DOI: 10.1177/17588359221080298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
93 Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2022:gutjnl-2021-325918. [PMID: 35197323 DOI: 10.1136/gutjnl-2021-325918] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
94 McVey JC, Green BL, Ruf B, McCallen JD, Wabitsch S, Subramanyam V, Diggs LP, Heinrich B, Greten TF, Ma C. NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice. iScience 2022;25:103847. [PMID: 35198900 DOI: 10.1016/j.isci.2022.103847] [Reference Citation Analysis]
95 Hernaez R, Peck-Radosavljevic M. MAFLD, HCC and the dilemma of (changing) terminology in liver diseases. Gut 2022:gutjnl-2022-326992. [PMID: 35169004 DOI: 10.1136/gutjnl-2022-326992] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Dudek M, Lohr K, Donakonda S, Baumann T, Lüdemann M, Hegenbarth S, Dübbel L, Eberhagen C, Michailidou S, Yassin A, Prinz M, Popper B, Rose-John S, Zischka H, Knolle PA. IL-6-induced FOXO1 activity determines the dynamics of metabolism in CD8 T cells cross-primed by liver sinusoidal endothelial cells. Cell Rep 2022;38:110389. [PMID: 35172161 DOI: 10.1016/j.celrep.2022.110389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. β-Catenin signaling in hepatocellular carcinoma. J Clin Invest 2022;132:e154515. [PMID: 35166233 DOI: 10.1172/JCI154515] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
98 Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology 2022;75:473-88. [PMID: 34923653 DOI: 10.1002/hep.32285] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
99 Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Xue D, Han J, Liang Z, Jia L, Liu Y, Tuo H, Peng Y. Current Perspectives on the Unique Roles of Exosomes in Drug Resistance of Hepatocellular Carcinoma. JHC 2022;Volume 9:99-112. [DOI: 10.2147/jhc.s351038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Murtha-Lemekhova A, Fuchs J, Feiler S, Schulz E, Teroerde M, Kalkum E, Klotz R, Billeter A, Probst P, Hoffmann K. Is metabolic syndrome a risk factor in hepatectomy? A meta-analysis with subgroup analysis for histologically confirmed hepatic manifestations. BMC Med 2022;20:47. [PMID: 35101037 DOI: 10.1186/s12916-022-02239-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Wang H, Zhou Y, Xu H, Wang X, Zhang Y, Shang R, O'Farrell M, Roessler S, Sticht C, Stahl A, Evert M, Calvisi DF, Zeng Y, Chen X. Therapeutic efficacy of FASN inhibition in preclinical models of HCC. Hepatology 2022. [PMID: 35076948 DOI: 10.1002/hep.32359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
103 Cammarota A, Zanuso V, D’alessio A, Pressiani T, Personeni N, Rimassa L. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Maestri M, Pallozzi M, Santopaolo F, Cerrito L, Pompili M, Gasbarrini A, Ponziani FR. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
105 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
106 Tran NH. Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications. Curr Oncol Rep. [DOI: 10.1007/s11912-021-01160-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Nishina S, Hino K. CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma. Cancers 2022;14:454. [DOI: 10.3390/cancers14020454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Zhang C, Liu S, Yang M. Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. Front Endocrinol (Lausanne) 2021;12:808526. [PMID: 35002979 DOI: 10.3389/fendo.2021.808526] [Reference Citation Analysis]
109 Amioka K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Murakami S, Yano S, Naruto K, Ando Y, Kosaka Y, Fujii Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Moriya T, Naeshiro N, Nonaka M, Hyogo H, Aisaka Y, Azakami T, Hiramatsu A, Aikata H. Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2022;14:320. [PMID: 35053484 DOI: 10.3390/cancers14020320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Burgio V, Iavarone M, Di Costanzo GG, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Celsa C, Foschi FG, Silletta M, Amoruso DC, Rimini M, Bruccoleri M, Tortora R, Campani C, Soldà C, Viola MG, Forgione A, Conti F, Salani F, Catanese S, Giacchetto CM, Fulgenzi C, Coppola C, Lampertico P, Pellino A, Rancatore G, Cabibbo G, Ratti F, Pedica F, Della Corte A, Colombo M, De Cobelli F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Cancer Manag Res 2021;13:9379-89. [PMID: 34992463 DOI: 10.2147/CMAR.S330195] [Reference Citation Analysis]
111 Reinkens T, Stalke A, Huge N, Vajen B, Eilers M, Schäffer V, Dittrich-Breiholz O, Schlegelberger B, Illig T, Skawran B. Ago-RIP Sequencing Identifies New MicroRNA-449a-5p Target Genes Increasing Sorafenib Efficacy in Hepatocellular Carcinoma. J Cancer 2022;13:62-75. [PMID: 34976171 DOI: 10.7150/jca.66016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Arvanitakis K, Koletsa T, Mitroulis I, Germanidis G. Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy. Cancers (Basel) 2022;14:226. [PMID: 35008390 DOI: 10.3390/cancers14010226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
113 Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? Front Oncol 2021;11:803133. [PMID: 34976841 DOI: 10.3389/fonc.2021.803133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Russo FP, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P, Farinati F. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int J Mol Sci 2022;23:500. [PMID: 35008926 DOI: 10.3390/ijms23010500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
115 Shao L, Yu X, Han Q, Zhang X, Lu N, Zhang C. Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. OncoImmunology 2022;11:2010894. [DOI: 10.1080/2162402x.2021.2010894] [Reference Citation Analysis]
116 Lu L, Zhan M, Li X, Zhang H, Dauphars DJ, Jiang J, Yin H, Li S, Luo S, Li Y, He Y. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology 2022;3:118-27. [DOI: 10.1016/j.crimmu.2022.05.003] [Reference Citation Analysis]
117 Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00385-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
118 Xu B, Sun HC. Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opin Investig Drugs 2021;:1-10. [PMID: 34937475 DOI: 10.1080/13543784.2022.2022121] [Reference Citation Analysis]
119 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
120 Ao H, Xin Z, Jian Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. Biomark Res 2021;9:91. [PMID: 34930486 DOI: 10.1186/s40364-021-00348-y] [Reference Citation Analysis]
121 Karin N. Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones? Cancers (Basel) 2021;13:6317. [PMID: 34944943 DOI: 10.3390/cancers13246317] [Reference Citation Analysis]
122 Kim MJ, Ha SJ. Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy. Front Cell Dev Biol 2021;9:767466. [PMID: 34901012 DOI: 10.3389/fcell.2021.767466] [Reference Citation Analysis]
123 Zhang C, Yang M. Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion. Front Med (Lausanne) 2021;8:789859. [PMID: 34869507 DOI: 10.3389/fmed.2021.789859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
124 Astle JM, Huang H. Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications. Front Oncol 2021;11:704464. [PMID: 34858804 DOI: 10.3389/fonc.2021.704464] [Reference Citation Analysis]
125 Campani C, Capone M, Liotta F, Arena U, Adotti V, Di Bonaventura C, Aburas S, Colagrande S, Calistri L, Annunziato F, Marra F. Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. Dig Liver Dis 2021:S1590-8658(21)00850-1. [PMID: 34876355 DOI: 10.1016/j.dld.2021.11.010] [Reference Citation Analysis]
126 Rimini M, Kudo M, Tada T, Shigeo S, Kang W, Suda G, Jefremow A, Burgio V, Iavarone M, Tortora R, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Kumada T, Iwamoto H, Aoki T, Goh MJ, Sakamoto N, Siebler J, Hiraoka A, Niizeki T, Ueshima K, Sho T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Cucchetti A, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open 2021;6:100330. [PMID: 34847382 DOI: 10.1016/j.esmoop.2021.100330] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
127 Cataldi M, Manco F, Tarantino G. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. Int J Mol Sci 2021;22:12947. [PMID: 34884762 DOI: 10.3390/ijms222312947] [Reference Citation Analysis]
128 Clavería-Cabello A, Avila MA. HIF2α Activation in NASH: A New Force Pushing Toward HCC. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00239-3. [PMID: 34848185 DOI: 10.1016/j.jcmgh.2021.11.005] [Reference Citation Analysis]
129 Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01258-1. [PMID: 34813942 DOI: 10.1016/j.cgh.2021.11.020] [Reference Citation Analysis]
130 Cheon J, Yoo C, Hong JY, Kim HS, Lee DW, Lee MA, Kim JW, Kim I, Oh SB, Hwang JE, Chon HJ, Lim HY. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver Int 2021. [PMID: 34792284 DOI: 10.1111/liv.15102] [Reference Citation Analysis]
131 Mohr R, Tacke F. Therapie des hepatozellulären Karzinoms – eine neue Dekade? Drug Res (Stuttg) 2021;71:S22-3. [PMID: 34788884 DOI: 10.1055/a-1606-5955] [Reference Citation Analysis]
132 Hirsova P, Bamidele AO, Wang H, Povero D, Revelo XS. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Front Endocrinol (Lausanne) 2021;12:760860. [PMID: 34777255 DOI: 10.3389/fendo.2021.760860] [Reference Citation Analysis]
133 Thompson SM, Suman G, Torbenson MS, Chen ZE, Jondal DE, Patra A, Ehman EC, Andrews JC, Fleming CJ, Welch BT, Kurup AN, Roberts LR, Watt KD, Truty MJ, Cleary SP, Smoot RL, Heimbach JK, Tran NH, Mahipal A, Yin J, Zemla T, Wang C, Fogarty Z, Jacobson M, Kemp BJ, Venkatesh SK, Johnson GB, Woodrum DA, Goenka AH. PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68 Ga-PSMA-11 PET Using Cyclotron-Produced 68 Ga. Hepatol Commun 2021. [PMID: 34783177 DOI: 10.1002/hep4.1861] [Reference Citation Analysis]
134 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
135 Albano E, Sutti S. The paradox role of cytotoxic T-lymphocytes in NAFLD-associated hepatocellular carcinoma. Hepatobiliary Surg Nutr 2021;10:705-7. [PMID: 34760980 DOI: 10.21037/hbsn-21-243] [Reference Citation Analysis]
136 Lan XB, Papatheodoridis G, Teng YX, Zhong JH. The upward trend in the immunotherapy utilization for hepatobiliary cancers. Hepatobiliary Surg Nutr 2021;10:692-5. [PMID: 34760976 DOI: 10.21037/hbsn-21-342] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Eso Y, Seno H. Optimization of immunotherapy for patients with hepatobiliary cancer. Hepatobiliary Surg Nutr 2021;10:717-9. [PMID: 34760984 DOI: 10.21037/hbsn-21-207] [Reference Citation Analysis]
138 Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2021. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Reference Citation Analysis]
139 Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S, Wada N, Kubota K, Tsuruya K, Shimma Y, Hiroki I, Takuya E, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H, Morimoto M, Numata K, Kusano C, Kagawa T, Maeda S. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatol Res 2021. [PMID: 34761470 DOI: 10.1111/hepr.13732] [Reference Citation Analysis]
140 Lewinska M, Santos-Laso A, Arretxe E, Alonso C, Zhuravleva E, Jimenez-Agüero R, Eizaguirre E, Pareja MJ, Romero-Gómez M, Jimenez MA, Suppli MP, Knop FK, Oversoe SK, Villadsen GE, Decaens T, Carrilho FJ, de Oliveira CP, Sangro B, Macias RIR, Banales JM, Andersen JB. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine 2021;73:103661. [PMID: 34740106 DOI: 10.1016/j.ebiom.2021.103661] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2021. [PMID: 34741169 DOI: 10.1038/s41577-021-00639-3] [Reference Citation Analysis]
142 Torrens L, Montironi C, Puigvehí M, Mesropian A, Leslie J, Haber PK, Maeda M, Balaseviciute U, Willoughby CE, Abril-Fornaguera J, Piqué-Gili M, Torres-Martín M, Peix J, Geh D, Ramon-Gil E, Saberi B, Friedman SL, Mann DA, Sia D, Llovet JM. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology 2021;74:2652-69. [PMID: 34157147 DOI: 10.1002/hep.32023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
143 Tomonari T, Sato Y, Tanaka H, Mitsuhashi T, Hirao A, Tanaka T, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Takayama T. Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open 2021;5:1275-83. [PMID: 34816013 DOI: 10.1002/jgh3.12663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol 2021;101:108322. [PMID: 34735916 DOI: 10.1016/j.intimp.2021.108322] [Reference Citation Analysis]
145 Kudo M. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers (Basel) 2021;13:5475. [PMID: 34771637 DOI: 10.3390/cancers13215475] [Reference Citation Analysis]
146 Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]
147 Shimose S, Hiraoka A, Nakano M, Iwamoto H, Tanaka M, Tanaka T, Noguchi K, Aino H, Ogata K, Kajiwara M, Itano S, Yokokura Y, Yamaguchi T, Kawano H, Matsukuma N, Suga H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Kawaguchi T, Koga H, Torimura T. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Med 2021. [PMID: 34693661 DOI: 10.1002/cam4.4367] [Reference Citation Analysis]
148 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines 2021;9:1524. [PMID: 34829753 DOI: 10.3390/biomedicines9111524] [Reference Citation Analysis]
149 Schultheiß M, Bengsch B, Thimme R. [Hepatocellular Carcinoma]. Dtsch Med Wochenschr 2021;146:1411-20. [PMID: 34670284 DOI: 10.1055/a-1226-3047] [Reference Citation Analysis]
150 Nakatsu G. Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma. J Gastroenterol Hepatol 2021. [PMID: 34665475 DOI: 10.1111/jgh.15715] [Reference Citation Analysis]
151 Ding Z, Dong Z, Chen Z, Hong J, Yan L, Li H, Yao S, Yan Y, Yang Y, Yang C, Li T. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. Front Immunol 2021;12:733530. [PMID: 34659220 DOI: 10.3389/fimmu.2021.733530] [Reference Citation Analysis]
152 Fan C, Kam S, Ramadori P. Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer. Cancers (Basel) 2021;13:5250. [PMID: 34680398 DOI: 10.3390/cancers13205250] [Reference Citation Analysis]
153 Yang M, Kimchi ET, Staveley-O'Carroll KF, Li G. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity. Int J Mol Sci 2021;22:11037. [PMID: 34681695 DOI: 10.3390/ijms222011037] [Reference Citation Analysis]
154 Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol 2021:S0168-8278(21)02100-0. [PMID: 34648895 DOI: 10.1016/j.jhep.2021.09.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 22.0] [Reference Citation Analysis]
155 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
156 Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1195-207. [PMID: 34595140 DOI: 10.2147/JHC.S322289] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Pinato DJ, Murray SM, Forner A, Kaneko T, Fessas P, Toniutto P, Mínguez B, Cacciato V, Avellini C, Diaz A, Boyton RJ, Altmann DM, Goldin RD, Akarca AU, Marafioti T, Mauri FA, Casagrande E, Grillo F, Giannini E, Bhoori S, Mazzaferro V. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer 2021;9:e003311. [PMID: 34593621 DOI: 10.1136/jitc-2021-003311] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
158 Venniyoor A, Al Farsi AA, Al Bahrani B. The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC). Cureus 2021;13:e17320. [PMID: 34557366 DOI: 10.7759/cureus.17320] [Reference Citation Analysis]
159 He Y, Lu M, Che J, Chu Q, Zhang P, Chen Y. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Front Oncol 2021;11:716844. [PMID: 34552872 DOI: 10.3389/fonc.2021.716844] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Giannakoulis VG, Dubovan P, Papoutsi E, Kataki A, Koskinas J. Senescence in HBV-, HCV- and NAFLD- Mediated Hepatocellular Carcinoma and Senotherapeutics: Current Evidence and Future Perspective. Cancers (Basel) 2021;13:4732. [PMID: 34572959 DOI: 10.3390/cancers13184732] [Reference Citation Analysis]
161 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
162 Marin JJG, Romero MR, Herraez E, Asensio M, Ortiz-Rivero S, Sanchez-Martin A, Fabris L, Briz O. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Semin Liver Dis 2021. [PMID: 34544160 DOI: 10.1055/s-0041-1735631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
164 Eso Y, Taura K, Seno H. Does immune checkpoint inhibitor exhibit limited efficacy against non-viral hepatocellular carcinoma?: A review of clinical trials. Hepatol Res 2021. [PMID: 34520619 DOI: 10.1111/hepr.13712] [Reference Citation Analysis]
165 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
166 Wang H, Chen X, Calvisi DF. Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opin Ther Targets 2021;25:645-58. [PMID: 34477018 DOI: 10.1080/14728222.2021.1976142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Yang X, Lu D, Wang R, Lian Z, Lin Z, Zhuo J, Chen H, Yang M, Tan W, Yang M, Wei X, Wei Q, Zheng S, Xu X. Single-cell profiling reveals distinct immune phenotypes that contribute to ischaemia-reperfusion injury after steatotic liver transplantation. Cell Prolif 2021;54:e13116. [PMID: 34469018 DOI: 10.1111/cpr.13116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
169 Kudo M. Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. Hepatobiliary Surg Nutr 2021;10:522-5. [PMID: 34430534 DOI: 10.21037/hbsn-21-203] [Reference Citation Analysis]
170 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol 2021;15:1245-51. [PMID: 34431725 DOI: 10.1080/17474124.2021.1973431] [Reference Citation Analysis]
171 Koessler T, Alsina M, Arnold D, Ben-Aharon I, Lutz MP, Obermannova R, Peeters M, Sclafani F, Smyth E, Valle JW, Wagner AD, Wyrwicz L, Fontana E, Moehler M. Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. Br J Cancer 2021;125:911-9. [PMID: 34426663 DOI: 10.1038/s41416-021-01474-y] [Reference Citation Analysis]
172 Morita M, Nishida N, Sakai K, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Nishio K, Kobayashi Y, Kakimi K, Kudo M. Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. Liver Cancer 2021;10:380-93. [PMID: 34414125 DOI: 10.1159/000516899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
173 Kudo M. Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma? Liver Cancer 2021;10:289-95. [PMID: 34414117 DOI: 10.1159/000517841] [Reference Citation Analysis]
174 Hindson J. T cells in NASH and liver cancer: pathology and immunotherapy. Nat Rev Gastroenterol Hepatol 2021;18:367. [PMID: 33948024 DOI: 10.1038/s41575-021-00461-1] [Reference Citation Analysis]
175 D'Alessio A, Cammarota A, Zanuso V, Pressiani T, Personeni N, Rimassa L. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Rev Anticancer Ther 2021;21:927-39. [PMID: 34167423 DOI: 10.1080/14737140.2021.1948329] [Reference Citation Analysis]
176 Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Aoki T, Tanaka T, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep 2021;11:16663. [PMID: 34404856 DOI: 10.1038/s41598-021-96089-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
177 Suzuki H, Iwamoto H, Nakano M, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Kuromatsu R, Niizeki T, Okamura S, Shimose S, Shirono T, Noda Y, Kamachi N, Yano H, Kawaguchi A, Koga H, Torimura T. Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments. Transl Oncol 2021;14:101201. [PMID: 34388691 DOI: 10.1016/j.tranon.2021.101201] [Reference Citation Analysis]
178 Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells 2021;10:2034. [PMID: 34440803 DOI: 10.3390/cells10082034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J Hepatocell Carcinoma 2021;8:887-97. [PMID: 34386437 DOI: 10.2147/JHC.S284440] [Reference Citation Analysis]
180 von Bülow V, Lichtenberger J, Grevelding CG, Falcone FH, Roeb E, Roderfeld M. Does Schistosoma Mansoni Facilitate Carcinogenesis? Cells 2021;10:1982. [DOI: 10.3390/cells10081982] [Reference Citation Analysis]
181 Komiyama S, Numata K, Ogushi K, Chuma M, Tanaka R, Chiba S, Otani M, Inayama Y, Nakano M, Maeda S. Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report. Diagnostics (Basel) 2021;11:1394. [PMID: 34441328 DOI: 10.3390/diagnostics11081394] [Reference Citation Analysis]
182 Lange NF, Radu P, Dufour JF. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. J Hepatol 2021:S0168-8278(21)01954-1. [PMID: 34339764 DOI: 10.1016/j.jhep.2021.07.025] [Reference Citation Analysis]
183 Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 2021;21:541-57. [PMID: 34326518 DOI: 10.1038/s41568-021-00383-9] [Reference Citation Analysis]
184 Galle PR, Abou-Alfa GK. Decision making in systemic therapy of hepatocellular carcinoma: Should we pay attention to disease aetiology? J Hepatol 2021;75:763-4. [PMID: 34311000 DOI: 10.1016/j.jhep.2021.07.014] [Reference Citation Analysis]
185 Zhang C, Yang M. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3740. [PMID: 34359642 DOI: 10.3390/cancers13153740] [Reference Citation Analysis]
186 Rudalska R, Zender L, Dauch D. Exploiting lipotoxicity for the treatment of liver cancer. Br J Cancer 2021. [PMID: 34302061 DOI: 10.1038/s41416-021-01479-7] [Reference Citation Analysis]
187 Huschka H, Mihm S. Hepatic IFNL4 Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology. Int J Mol Sci 2021;22:7803. [PMID: 34360569 DOI: 10.3390/ijms22157803] [Reference Citation Analysis]
188 Nishida N. Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3666. [PMID: 34359568 DOI: 10.3390/cancers13153666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
189 Nishida N. Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3666. [PMID: 34359568 DOI: 10.3390/cancers13153666] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Shigesawa T, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatol Res 2021;51:979-89. [PMID: 34245216 DOI: 10.1111/hepr.13693] [Reference Citation Analysis]
191 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-Selcanova S, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort. J Clin Med 2021;10:3186. [PMID: 34300352 DOI: 10.3390/jcm10143186] [Reference Citation Analysis]
192 O'Leary K. T cell drivers in NASH-HCC. Nat Rev Cancer 2021;21:341. [PMID: 33864034 DOI: 10.1038/s41568-021-00362-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Rizzo A, Dadduzio V, Ricci AD, Massari F, Di Federico A, Gadaleta-Caldarola G, Brandi G. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs 2021;:1-8. [PMID: 34167433 DOI: 10.1080/13543784.2021.1948532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
195 Piñero F, da Fonseca LG. Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups? World J Gastroenterol 2021; 27(24): 3429-3439 [PMID: 34239261 DOI: 10.3748/wjg.v27.i24.3429] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
196 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]
197 Haber PK, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, Buckstein M, Kim E, Villanueva A, Schwartz M, Llovet JM. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology 2021;161:879-98. [PMID: 34126063 DOI: 10.1053/j.gastro.2021.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
198 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan). Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Cancer Rep (Hoboken) 2022;5:e1464. [PMID: 34114752 DOI: 10.1002/cnr2.1464] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
199 Peng Y, Wong CC, Yu J. The paradox of immunotherapy in NASH-HCC. Signal Transduct Target Ther 2021;6:228. [PMID: 34112767 DOI: 10.1038/s41392-021-00654-9] [Reference Citation Analysis]
200 Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T, On Behalf Of The Kurume Liver Cancer Study Group Of Japan. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers (Basel) 2021;13:2786. [PMID: 34205099 DOI: 10.3390/cancers13112786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
201 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2021:S0168-8278(21)00326-3. [PMID: 33992698 DOI: 10.1016/j.jhep.2021.04.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
203 Hirsova P, Gores GJ. Fatty liver progression and carcinogenesis: Beware of pathogenic T cells. Med 2021;2:453-5. [DOI: 10.1016/j.medj.2021.04.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
205 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
206 Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T. Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers (Basel) 2021;13:1949. [PMID: 33919570 DOI: 10.3390/cancers13081949] [Reference Citation Analysis]